CNBC Investing Club

Cramer's Investing Club: Recent drop in a portfolio drug stock only a minor setback

Eli Lilly Pharmaceutical company logo
SOPA Images | LightRocket | Getty Images

(This article was sent first to members of the CNBC Investing Club with Jim Cramer. To get the real-time updates in your inbox, subscribe here.)

After the big run last week, Eli Lilly (LLY) shares have backed off to a bit to the mid-$260s due to a combination of investors booking profits where they had them in a volatile market and rotational pressure from the risk-on attitude of Tuesday's rally.